Development of an IL-4/IL-13:IL-4Rα in vitro to in vivo Translational Platform in a Model of Respiratory Disease

A Translational IL-4/IL-13 Platform for Respiratory Drug Discovery

Targeting the IL-4Rα pathway to tackle type 2 inflammation in Asthma and COPD

Type 2 inflammation plays a central role in asthma and COPD, driven by IL-4 and IL-13 signaling through IL-4Rα. While Dupilumab has paved the way, the need for next-generation IL-4Rα-targeted therapies continues.

To accelerate discovery, we developed a scalable in vitro to in vivo platform to assess IL-4/IL-13 pathway modulators. Validated with Dupilumab and the JAK inhibitor Tofacitinib, this system enables functional screening and characterization of new IL-4Rα-targeting compounds.

👉 Download the free poster to explore this powerful tool for respiratory drug development.